120 related articles for article (PubMed ID: 37936296)
1. Temporal changes in coronary plaque as assessed by an artificial intelligence-based optical coherence tomography: from the first-in-human trial on DREAMS 3G scaffold.
Garcia-Garcia HM; Waksman R; Melaku GD; Garg M; Beyene S; Wlodarczak A; Kerai A; Levine MB; van der Schaaf RJ; Torzewski J; Ferdinande B; Escaned J; Iglesias JF; Bennett J; Toth GG; Joner M; Toelg R; Wiemer M; Olivecrona G; Vermeersch P; Haude M
Eur Heart J Cardiovasc Imaging; 2024 Mar; 25(4):491-497. PubMed ID: 37936296
[TBL] [Abstract][Full Text] [Related]
2. Impact of procedural characteristics on coronary vessel wall healing following implantation of second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary artery lesions: an optical coherence tomography analysis.
Ozaki Y; Garcia-Garcia HM; Hideo-Kajita A; Kuku KO; Haude M; Ince H; Abizaid A; Tölg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Escaned J; Dijkstra J; Waksman R
Eur Heart J Cardiovasc Imaging; 2019 Aug; 20(8):916-924. PubMed ID: 30590578
[TBL] [Abstract][Full Text] [Related]
3. Reproducibility of an artificial intelligence optical coherence tomography software for tissue characterization: Implications for the design of longitudinal studies.
Garg M; Garcia-Garcia HM; Calderón AT; Gupta J; Sortur S; Levine MB; Singla P; Picchi A; Sardella G; Adamo M; Frigoli E; Limbruno U; Rigattieri S; Diletti R; Boccuzzi G; Zimarino M; Contarini M; Russo F; Calabro P; Andò G; Varbella F; Garducci S; Palmieri C; Briguori C; Sánchez JS; Valgimigli M
Cardiovasc Revasc Med; 2024 Jan; 58():79-87. PubMed ID: 37474355
[TBL] [Abstract][Full Text] [Related]
4. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study.
Haude M; Wlodarczak A; van der Schaaf RJ; Torzewski J; Ferdinande B; Escaned J; Iglesias JF; Bennett J; Toth GG; Joner M; Toelg R; Wiemer M; Olivecrano G; Vermeersch P; Garcia-Garcia HM; Waksman R
EuroIntervention; 2023 Aug; 19(5):e414-e422. PubMed ID: 37334655
[TBL] [Abstract][Full Text] [Related]
5. Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100.
Boeder NF; Dörr O; Bauer T; Mattesini A; Elsässer A; Liebetrau C; Achenbach S; Hamm CW; Nef HM
Int J Cardiol; 2017 Nov; 246():74-79. PubMed ID: 28579164
[TBL] [Abstract][Full Text] [Related]
6. Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years.
Onuma Y; Honda Y; Asano T; Shiomi H; Kozuma K; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Hanaoka KI; Tanabe K; Okada K; Kitahara H; Ono M; Kusano H; Rapoza R; Simonton C; Popma JJ; Stone GW; Fitzgerald PJ; Serruys PW; Kimura T
JACC Cardiovasc Interv; 2020 Jan; 13(1):116-127. PubMed ID: 31918929
[TBL] [Abstract][Full Text] [Related]
7. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
8. In vivo serial invasive imaging of the second-generation drug-eluting absorbable metal scaffold (Magmaris - DREAMS 2G) in de novo coronary lesions: Insights from the BIOSOLVE-II First-In-Man Trial.
Garcia-Garcia HM; Haude M; Kuku K; Hideo-Kajita A; Ince H; Abizaid A; Tölg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Escaned J; Dijkstra J; Waksman R
Int J Cardiol; 2018 Mar; 255():22-28. PubMed ID: 29292064
[TBL] [Abstract][Full Text] [Related]
9. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
[TBL] [Abstract][Full Text] [Related]
10. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
11. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.
Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Garcia-Garcia HM; Waksman R
Lancet; 2016 Jan; 387(10013):31-9. PubMed ID: 26470647
[TBL] [Abstract][Full Text] [Related]
12. Serial 3-Dimensional Optical Coherence Tomography Assessment of Jailed Side-Branch by Second-Generation Drug-Eluting Absorbable Metal Scaffold (from the BIOSOLVE-II Trial).
Ozaki Y; Garcia-Garcia HM; Hideo-Kajita A; Kuku KO; Haude M; Ince H; Abizaid A; Tölg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Escaned J; Waksman R
Am J Cardiol; 2019 Apr; 123(7):1044-1051. PubMed ID: 30683424
[TBL] [Abstract][Full Text] [Related]
13. Serial Baseline, 12-, 24-, and 60-Month Optical Coherence Tomography Evaluation of ST Segment Elevation Myocardial Infarction Patients Treated with Absorb Bioresorbable Vascular Scaffold.
Koltowski L; Tomaniak M; Ochijewicz D; Zieliński K; Proniewska K; Malinowski KP; Zaleska M; Maksym J; Roleder T; Partyka L; Kochman W; Filipiak KJ; Opolski G; Kochman J
Am J Cardiol; 2021 Sep; 155():23-31. PubMed ID: 34315572
[TBL] [Abstract][Full Text] [Related]
14. Effect of Plaque Composition, Morphology, and Burden on DESolve Novolimus-Eluting Bioresorbable Vascular Scaffold Expansion and Eccentricity - An Optical Coherence Tomography Analysis.
Boeder NF; Dörr O; Bauer T; Elsässer A; Möllmann H; Achenbach S; Hamm CW; Nef HM
Cardiovasc Revasc Med; 2019 Jun; 20(6):480-484. PubMed ID: 30638889
[TBL] [Abstract][Full Text] [Related]
15. First Report of Edge Vascular Response at 12 Months of Magmaris, A Second-Generation Drug-Eluting Resorbable Magnesium Scaffold, Assessed by Grayscale Intravascular Ultrasound, Virtual Histology, and Optical Coherence Tomography. A Biosolve-II Trial Sub-Study.
Hideo-Kajita A; Garcia-Garcia HM; Haude M; Joner M; Koolen J; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Teik LS; Escaned J; Azizi V; Kuku KO; Ozaki Y; Dan K; Waksman R
Cardiovasc Revasc Med; 2019 May; 20(5):392-398. PubMed ID: 31079817
[TBL] [Abstract][Full Text] [Related]
16. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
[TBL] [Abstract][Full Text] [Related]
17. The OCT-ORION Study: A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-Eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.
Lee SWL; Tam FCC; Lam SCC; Kong SL; Shea CP; Chan KKW; Wong MKL; Chan MPH; Wong AYT; Yung ASY; Lam YM; Zhang LW; Wu KKY; Mintz GS; Maehara A
Circ Cardiovasc Interv; 2018 Apr; 11(4):e006034. PubMed ID: 29654119
[TBL] [Abstract][Full Text] [Related]
18. Optical coherence tomography assessment of incidence, morphological characteristics, and spontaneous healing course of edge dissections following percutaneous coronary intervention with stent implantation in patients with non-ST segment elevation myocardial infarction.
Antonsen L; Thayssen P; Hansen HS; Junker A; Veien KT; Hansen KN; Hougaard M; Jensen LO
Int J Cardiol; 2016 Nov; 223():466-474. PubMed ID: 27544607
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
[TBL] [Abstract][Full Text] [Related]
20. Long-term consequences of optical coherence tomography findings during percutaneous coronary intervention: the Centro Per La Lotta Contro L'infarto - Optimization Of Percutaneous Coronary Intervention (CLI-OPCI) LATE study.
Prati F; Romagnoli E; La Manna A; Burzotta F; Gatto L; Marco V; Fineschi M; Fabbiocchi F; Versaci F; Trani C; Tamburino C; Alfonso F; Mintz GS
EuroIntervention; 2018 Jul; 14(4):e443-e451. PubMed ID: 29633940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
